A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.本發明係關於一種促凋亡固態分散劑，其包含分散於固態基質中的基本上呈非結晶形式之Bcl-2家族蛋白抑制化合物，例如ABT-263，該固態基質包含(a)醫藥上可接受之水溶性聚合物載劑及(b)醫藥上可接受之表面活性劑。本發明亦係關於製備此一固態分散劑之方法，其包括使該化合物、該聚合物載劑及該表面活性劑溶解於適宜溶劑中，及去除該溶劑，以提供固態基質，該固態基質包含該聚合物載劑及該表面活性劑且具有該基本上呈非結晶形式分散於其中之化合物。該固態分散劑適於經口投與有需要之個體，用於治療特徵在於一或多種抗凋亡Bcl-2家族蛋白過表現之疾病，例如癌症。
